Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy

Atezolizumab is now the standard treatment for extensive-stage small cell lung cancer (ES-SCLC). Herein, we investigated the prognostic role of inflammatory markers in patients treated with atezolizumab plus chemotherapy and evaluated the efficacy and safety of adding atezolizumab to chemotherapy fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Kutlu, Yasin, Aydin, Sabin Goktas, Bilici, Ahmet, Oven, Bala Basak, Olmez, Omer Fatih, Acikgoz, Ozgur, Hamdard, Jamshid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101285/
https://www.ncbi.nlm.nih.gov/pubmed/37058061
http://dx.doi.org/10.1097/MD.0000000000033432

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101285/
https://www.ncbi.nlm.nih.gov/pubmed/37058061
http://dx.doi.org/10.1097/MD.0000000000033432

Ejemplares similares